
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 20, 2026, 8:00 AM ET
Allogene will host an in-person event at the 68th American Society of Hematology Annual Meeting on December 13, 2026, in New Orleans.
Nasdaq Global Select Market · $ALLODonor-derived cell therapyLymphoma and autoimmune diseaseDevelopment and financing risk
ALLO Stock Hub: Allogene Therapeutics News, Lymphoma and Autoimmune Trials
Allogene is testing whether an investigational donor-derived cell therapy can improve outcomes for lymphoma patients whose blood still shows signs of disease after first-line treatment. Its pivotal trial has an early molecular signal, with clinical outcomes still blinded. Separate Phase 1 data showed a skin-score improvement in eight of ten people with skin-predominant systemic sclerosis. Allogene reported $388.9 million in cash and investments at September 30 as it funded these studies. September Form 10-Q · November autoimmune results.
Full research report · PDF
Allogene Therapeutics, Inc. ($ALLO), research updated November 19, 2026
17 pages on lymphoma consolidation, autoimmune trials, kidney cancer, cash and financing. For personal use only: redistribution prohibited.
Next scheduled event
December 2, 2026 · Piper Sandler Healthcare Conference
The company lists an investor appearance in New York. Allogene will also host a physician panel on access to CAR T therapy on December 13 at the American Society of Hematology annual meeting. December 2 event page · October 26 conference announcement · Allogene ASH announcement.
The next company-guided clinical update for ALPHA3 is in mid-2027. That update depends on available data, regulator feedback and trial oversight. Clinical timing and conditions.
ALLO stock at a glance
Chart analysis · JC
Technical chart analysis of $ALLO with bull and bear scenarios on JC Just Charts.
2026 accounting expense outlook
About $225 million
Company projection of annual operating expenses under U.S. accounting rules, November 5. Company guidance.
Where Allogene stands now
Cemacabtagene ansegedleucel, or cema-cel, is the lead lymphoma program. The pivotal Phase 2 ALPHA3 study enrolls people with residual disease detected using an investigational blood test after initial treatment. The clinical purpose is to test earlier intervention in a group usually observed without further immediate therapy. Enrollment and consistent access to the test matter because the opportunity begins with correctly identifying patients in remission who remain at risk. ALPHA3 design and risk factors.
Three programs with separate evidence. The Phase 1 autoimmune trial examines ALLO-329 across more than one condition and has reported initial results. ALLO-316 was studied in advanced kidney cancer, and Allogene is exploring strategic options for its next stage. Positive observations in one population leave separate clinical and commercial questions for the others. RESOLUTION first results · TRAVERSE strategy.
Constructive case
Randomized lymphoma outcomes eventually support treating patients selected by residual disease, and community sites consistently move eligible patients from testing to treatment.
Cautious case
The molecular signal fails to translate into fewer clinical events, expansion takes longer or the diagnostic and therapy require more resources than the company has allowed for.
Latest ALLO news
Nov 20, 2026
Allogene Therapeutics to Host Events at American Society of Hematology Annual Meeting 2026
Allogene Therapeutics will host an in-person event at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans on December 13, 2026. The event will feature new market research from a survey of 152 hematologists and oncologists and a moderated physician panel, with the research abstract to be published in a supplement to Blood. The pivotal ALPHA3 trial of cema-cel will also be featured at a Natera-hosted clinical trial showcase on December 12, 2026.
Nov 18, 2026
Allogene’s November Jefferies conference appearance
The company listed a November 18 appearance at Jefferies in London. Its November results release puts the next ALPHA3 clinical update in mid-2027.
Nov 16, 2026
Citadel-related filing reports Griffin’s beneficial ownership in Allogene
A joint Schedule 13G reported that Kenneth C. Griffin may be deemed to beneficially own 24,680,425 Allogene shares, or 7.1 percent, as of September 30. The filing shows how that total includes positions attributed to separate reporting entities.
Nov 12, 2026
Cellectis keeps cema-cel listed as a partnered program
Cellectis reported cema-cel in its partnered pipeline. Allogene expects an ALPHA3 clinical update in mid-2027 and targets completing enrollment of the randomized residual-disease-positive cohort by year-end 2027.
Nov 10, 2026
State Street falls below the five-percent Allogene reporting threshold
State Street reported 16,326,197 shares, or 4.7 percent, as of September 30. Its August filing had reported 5.5 percent as of June 30.
Nov 9, 2026
Allogene reports early safety and skin-score results in RESOLUTION
In Phase 1, six of 18 participants had a serious treatment-emergent adverse event. No dose-limiting toxicities were reported at the September 21 cutoff. Eight of 10 in the skin-predominant systemic sclerosis subgroup sustained an improvement of at least five points on the modified Rodnan skin score.
ALLO catalyst calendar
- April 13, 2026 — Allogene reported the planned early molecular analysis of the first 24 patients randomized to the two ongoing ALPHA3 arms. Company interim analysis · April release
- July 29, 2026 — Allogene announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track and Regenerative Medicine Advanced Therapy designations for cema-cel in first-line consolidation. Regulatory designations · Company disclosure
- November 5–6, 2026 — At the Society for Immunotherapy of Cancer meeting, Allogene presented TRAVERSE clinical findings, discussed access to donor-derived cell therapy and presented a separate preclinical poster. Past meeting program · Presentation descriptions
- November 5–6, 2026 — Allogene released results on November 5. The September Form 10-Q has a November 6 filing date. Annie Yoshiyama became interim principal financial officer upon Geoffrey Parker’s departure on November 6. Reported results and leadership transition · Results exhibit · Quarterly filing
- November 9, 2026 — Allogene disclosed initial Phase 1 RESOLUTION observations at the American College of Rheumatology meeting. Preliminary clinical report · Meeting results
- November 10, 2026 — State Street filed its September beneficial ownership report. Filed ownership disclosure · Schedule 13G
- November 12, 2026 — Cellectis retained cema-cel in its partner-program update. Partner disclosure · Cellectis results release
- November 16, 2026 — A Citadel group filed its September beneficial ownership report. Allogene was scheduled to present at the UBS Global Biopharma Conference in London. Filed ownership disclosure and past conference · Schedule 13G · Conference notices
- November 18, 2026 — Allogene was scheduled to present at the Jefferies Global Healthcare Conference in London. Past investor event · Webcast page
- December 2, 2026 — Allogene is scheduled at the Piper Sandler Healthcare Conference. Investor conference · Company event page
- December 12–15, 2026 — The American Society of Hematology annual meeting. Natera will present the ALPHA3 trial design on December 12 from 3:45 to 4:00 p.m. Central Time. Allogene will host a physician panel on access to CAR T therapy on December 13 from 8:00 to 9:00 a.m. Central Time. Natera-hosted trial showcase and Allogene-hosted panel · Meeting organizer · Allogene ASH announcement
- 2027 — Allogene plans a further RESOLUTION update. Company outlook · Study next steps
- Mid-2027 — Allogene expects its next clinical update for ALPHA3. An independent monitoring board is also due to review interim event-free survival data. Public disclosure depends on available data, regulatory feedback and trial oversight. Company outlook · Trial timetable
- Year-end 2027 — Allogene targets completion of enrollment in the randomized, residual-disease-positive portion of ALPHA3. Company target · Form 10-Q
- Mid-2028 — Allogene expects the primary event-free survival analysis of ALPHA3. Company estimate · Primary analysis schedule
Evidence by indication
Lymphoma after first-line treatment
A blood test identifies the patients being randomized. The key test is whether early treatment keeps patients free from events that matter clinically. ALPHA3 design and evidence.
Systemic sclerosis and other autoimmune disease
The November report emphasized skin-predominant systemic sclerosis. Longer follow-up and controlled comparisons would help establish what the early skin-score changes mean. RESOLUTION evidence.
Allogene Therapeutics, Inc. deep dive: the full analysis
The chapters examine the case for intervening after lymphoma treatment, the separate clinical programs, and the financing and licensing obligations behind them. The Merlintrader Research Library collects our dated biotech stock research reports.
01 Three ways the lymphoma and financing case can develop
ALPHA3 links a diagnostic decision to a treatment decision. For both to work in practice, a patient needs an interpretable blood sample within the applicable period, a site able to act on the result, and a treatment benefit that justifies giving cells to a patient for whom observation would otherwise be appropriate. A positive trial would address the last point. Consistent performance across different centers would inform the other two. Assay and site risks.
Bull scenario · Earlier intervention reduces clinical events
The pivotal trial finds a meaningful reduction in events among the eligible patients assigned to cema-cel. The selection test performs consistently, and treatment and monitoring can be delivered at a useful range of sites. As the main program strengthens, later autoimmune results could give Allogene another pathway to development or partnering without having to carry a full late-stage program on its own.
Base scenario · Enrollment progresses, with more work before commercialization
The lymphoma study advances through recruitment and the planned clinical update. The scope of what can be shared while the randomized trial continues remains limited. Selected autoimmune results justify further work, while the pace and cost of supporting enrollment, diagnostics and possible submissions draw on the balance already raised. The timing of the primary analysis becomes important relative to funding capacity.
Bear scenario · The screening and treatment proposition weakens
Recruitment slows, the selection test proves difficult to use across sites or treatment brings less durable benefit than the short-term blood measurements suggested. A licensing disruption or a delayed safety decision could raise costs while postponing the next pivotal milestone. Management might need to narrow spending or finance another period before the clinical case is settled.
What would falsify this reading
The thesis that cema-cel can move into earlier use depends on fewer relevant clinical events in the randomized target population. If the primary endpoint fails to show benefit, evidence of molecular clearance alone would carry less weight. Recruitment may also reveal a narrower eligible population than screening projections suggest, or demand for monitoring that limits use outside specialized centers. Primary endpoint and operational risks · ClinicalTrials.gov record.
For ALLO-329, a larger sample that loses the early skin-score benefit, needs frequent restart of background immunosuppression or develops more severe adverse events would weaken the idea that a shorter treatment course can materially improve care. Durability and organ outcomes will need to be evaluated by disease. For financing, the cash-use trend and actual program commitments will show whether Allogene can still fund its planned milestones into early 2029. Autoimmune outcomes · Liquidity and capital resources.
02 The clinical and commercial logic of donor-derived therapy
Allogene Therapeutics, Inc. develops chimeric antigen receptor (CAR) T-cell therapies for cancers and autoimmune diseases. The advanced programs use donor-derived cells. That creates a different supply model from autologous therapy, which starts with a patient’s own cells. A shared inventory could reduce the wait to obtain a treatment, depending on the ability to produce and release consistent lots and on how long the cells persist in recipients. A shorter supply timeline would address only part of the access problem. Assessing patients, covering treatment and providing follow-up are separate jobs. Company overview and manufacturing risks.
The lymphoma program measures the effect of acting at a different point in the treatment journey. A patient who has responded to first-line treatment may look well and have no immediate reason to start a new therapy under current practice. Minimal residual disease, or MRD, refers to signs that cancer remains despite the response. Treating that group could delay relapse if the assay identifies meaningful risk and if the cells change the subsequent clinical course. A diagnostic false positive could expose a patient to treatment without useful benefit, while a false negative could leave a high-risk patient in observation. Patient selection and assay risks · ALPHA3 study record.
Allogene plans to supply its investigational therapies from inventory if regulators approve them. Batch availability, the costs of transport and follow-up, and site capacity would determine how the approach works at scale. Allogene brought in Rocio Manghani as vice president of market access, evidence and strategy, according to its November results update. The work ahead includes obtaining evidence that payers and physicians can use, understanding reimbursement and preparing sites. The scale of clinical demand will still depend on the labeled population and the ability to identify it in time. Commercial preparation and executive appointment.
The company currently prioritizes cema-cel for large B-cell lymphoma (LBCL), ALLO-329 for autoimmune conditions, and ALLO-316 for advanced kidney cancer. The programs share a donor-derived approach but have different endpoints, conditioning questions and partners or funding needs. In oncology the economic question is whether the ability to supply cells on demand can support favorable medical outcomes in an appropriate population. In autoimmune disease, the burden of treatment is particularly important because the comparison would often involve ongoing medications. Program overview · Autoimmune trial.
03 The upcoming milestones have different evidentiary weight
After the December 2 Piper Sandler investor appearance, Natera will host a showcase on ALPHA3 trial design and Allogene will host a panel on CAR T access at the ASH Annual Meeting. An abstract on a survey of 152 U.S. hematologists and oncologists, examining barriers to CAR T adoption, was accepted for online publication and for the Blood meeting supplement. Piper Sandler event · November 5 survey disclosure · November 20 Allogene ASH announcement.
For ALPHA3, the company expects its next clinical update in mid-2027. The September filing also puts a planned interim event-free survival analysis in mid-2027 under an independent monitoring board. Allogene may remain blinded to some or all comparative results. Public disclosure will depend on available evidence, FDA feedback, recommendations from the monitoring board and the integrity of the ongoing trial. By year-end 2027 management aims to complete the randomized portion’s enrollment. Its stated primary event-free survival analysis window is mid-2028. A recruitment goal, a primary completion estimate and a publicly reported readout are distinct dates. The registry’s October 30 record gave an estimated primary completion in December 2027. The company’s later filing gives its separate estimate for the event-free survival analysis. Company timetable · Registry dates.
The latest first-in-human data are for ALLO-329. The November 9 disclosure sets a 2027 window for the next results. A larger update should clarify both how long the early skin findings persist and what is observed in other diseases. The registry describes an estimated 66 participants and primary completion in February 2028. These are estimates for the registered study. The number already assessed in the interim safety cohort refers to the September cutoff and differs from the estimated final enrollment. Study next steps · RESOLUTION study record.
04 ALPHA3 pairs a blood test with a randomized clinical question
ALPHA3 compares cema-cel consolidation with observation in people whose residual disease test is positive after initial chemoimmunotherapy. It includes patients in complete response and certain patients in partial remission for whom observation is appropriate under the study criteria. According to the September filing, the amended study expects about 220 patients in the randomized positive group. A separate observational group of about 140 people with a negative test is intended to characterize assay performance. This latter group does not randomize patients to treatment and is outside the primary comparison. Amended trial design and eligibility.
The same filing describes more than 80 active enrolling sites in the United States, Canada, South Korea and Australia, with approximately 100 expected globally and possible European expansion subject to approvals and implementation. Expanding a site network can make screening easier. The rate-limiting step may still be how often the test is completed in the required time and identifies an eligible result. Different practice settings can also differ in how readily a patient in remission is referred to an investigational consolidation study. The registry lists estimated enrollment of 250 in its October update. The later filing separately describes the two populations rather than treating the registry estimate as the planned total for both. Sites and enrollment · Registry enrollment estimate.
The primary endpoint, event-free survival, measures events such as starting another lymphoma treatment, progression or death. The company’s November 2026 investor presentation describes a blinded independent review committee for assessing that endpoint and says the trial is powered to detect a 50 percent reduction in event risk. That is a trial design assumption. November presentation, ALPHA3 design.
The planned early analysis addressed molecular response in the first 24 patients randomized to the two ongoing arms. At the day-45 assessment, seven of 12 treated patients and two of 12 assigned to observation tested negative. Circulating tumor DNA fell by a median 97.7 percent from baseline in the treatment group and increased by a median 26.6 percent in the observation group. Event-free survival, progression-free survival and overall survival results remained blinded. The results supported continuing the trial. Allogene states in its September filing that regulators do not accept residual-disease clearance as a surrogate endpoint in large B-cell lymphoma. The clinical value of the intervention will depend on the larger outcome comparison. April 13 futility assessment · September status of the primary endpoint.
Allogene reported managing ten of the first 12 treated patients as outpatients after infusion, with no treatment-related hospitalizations or serious adverse events at that cutoff. About a third of the earlier screening activity and treatment occurred in community cancer centers. Those observations describe the participating sites and patients. Larger-scale performance will depend on the distribution of centers and on monitoring during routine delivery. A small trial group with no specific severe event cannot estimate the upper end of the risk across broader use. Interim safety and community-site data.
An earlier ALPHA3 arm had a fatal serious adverse event associated with ALLO-647, part of the preparation for infusion. The participant developed liver failure in the setting of disseminated adenovirus infection and immunosuppression. Allogene deemed the event unrelated to cema-cel, discontinued that arm in July 2025 and continues to follow its participants. The April 2026 analysis covered the two ongoing arms. ALPHA3 safety history and risk factors.
In the prospective HOVON-902 cohort, Wang and colleagues reported in the February 2026 issue of the Journal of Clinical Oncology that end-of-treatment circulating tumor DNA identified patients with different outcomes after first-line care. Three-year progression-free survival estimates were 17 percent in patients with a positive residual disease test and 85 percent in patients with a negative test. The finding concerns prognosis in a cohort. It supports studying the marker for selection and leaves open whether changing treatment in response to that marker improves survival. ALPHA3 is designed to address intervention, a separate question from classification. Wang et al., Journal of Clinical Oncology, 2026 · Diagnostic and endpoint risks.
Published early studies provide a second piece of context. The combined Phase 1 ALPHA2 and ALPHA experience described 33 previously treated lymphoma patients who had never received CD19 CAR T therapy, with an overall response rate of 58 percent and a complete response rate of 42 percent. Median response duration was 23.1 months among patients who had a complete response. Serious treatment-emergent events were reported in 42 percent of patients. Those patients had relapsed or refractory disease. The balance of treatment benefit and risk after a first response in ALPHA3 will require its own results. Locke et al., Journal of Clinical Oncology, 2025.
Autologous therapy already has randomized clinical evidence in its own setting. ZUMA-7, published in the New England Journal of Medicine in 2022, compared second-line axicabtagene ciloleucel with standard care in 359 patients who had refractory disease or relapsed early after first-line therapy. The median event-free survival was 8.3 months with axicabtagene ciloleucel and 2.0 months with standard care. Allogene’s proposed consolidation step comes earlier and uses the study’s own test, population and control. The established alternative illustrates what an outcome-based evaluation measures once clinical events are sufficiently mature. Locke et al., NEJM, 2022.
05 Initial autoimmune results and the limits of a small safety cohort
RESOLUTION is an early study of ALLO-329 in systemic sclerosis, idiopathic inflammatory myopathies and systemic lupus erythematosus. The November 9 company presentation covers 18 people who had completed the initial 28-day safety assessment by September 21. Twelve of the participants had systemic sclerosis, including the ten with skin-predominant disease discussed in the efficacy analysis. Four had inflammatory myopathies and two had lupus. Each condition can affect function and organs differently. A finding concentrated in one subset needs disease-specific follow-up before it supports expectations for the full basket. Company disclosure and cutoff · Registered study populations.
Eight of the ten skin-predominant patients achieved and maintained an improvement of five points or more in the modified Rodnan skin score, a measure of skin thickening. Nine remained off background immunosuppressive therapy at the cutoff. The company reported the longest such interval as more than eight months and ongoing. Observations were reported across conditioning approaches, including in people treated without lymphodepletion, the preparatory reduction of lymphocytes. Follow-up length and the composition of each group vary. The result is a reason to ask for comparative evidence on durability, organ function and use of other treatment over time. November 9 efficacy observations · Scientific meeting poster.
Every patient in the interim report had at least one treatment-emergent adverse event. Three experienced an event of grade 3 or higher, and six had at least one serious treatment-emergent event of any grade. Cytokine release syndrome (CRS) occurred in four patients and was grade 1 or 2. Allogene reported no dose-limiting toxicities, grade 3 or higher CRS, graft-versus-host disease, immune effector cell-associated neurotoxicity syndrome or immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome in the evaluated group. The small cohort limits estimates of how often uncommon events may occur. Adverse-event table · Poster safety analysis.
The company is still evaluating treatment approaches with different preparatory burdens. Patients in different groups may have entered with different disease characteristics. The observations come from small, unrandomized groups. The effect of conditioning remains a question for larger studies. A prospective comparison would be useful for identifying whether recurrence, infection, blood-count changes or continued immunosuppression differ across groups. The regulator granted Fast Track designations in three studied indications, according to Allogene. The designations provide a pathway for interaction with the regulator as the evidence develops. Regulatory designations and study design · Study record.
06 Kidney cancer, safety and the search for a development partner
ALLO-316 addresses advanced clear cell renal cell carcinoma, a form of kidney cancer. The Phase 1 TRAVERSE population had previously progressed despite treatment, and patients received a median of four previous lines of therapy. Srour and colleagues describe 51 enrolled participants in the study as a whole. The September filing separately identifies 20 patients in the efficacy analysis of the expansion regimen and 22 in the Phase 1b safety population. The different denominators matter when a result is cited from the expansion. Srour et al., Journal of Clinical Oncology, 2026 · Expansion-cohort definitions.
The company reports confirmed objective responses in five of 20 participants in the Phase 1b efficacy cohort (25 percent). All five responses came from the 16 participants with high tumor CD70 expression. The estimate for that group was 31.3 percent with a wide 95 percent confidence interval, 11.0 to 58.7 percent. No responses were observed among the four lower-expression patients in this cohort. Biomarker selection could improve how a later study targets enrollment, but the small groups leave the size and reproducibility of the difference uncertain. Response counts and intervals · Peer-reviewed TRAVERSE paper.
In the 22-patient Phase 1b safety population, eight patients developed an immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome and two experienced grade 3 or higher events in that category. The September filing reports no treatment-related event of grade 5 in Phase 1b. In Phase 1a, the authors reported three fatal treatment-related events: cardiogenic shock, failure to thrive and sepsis. Allogene reported that changes to safety management appeared to improve control of the syndrome later in the study. Safety findings in Phase 1b · Full study, Phase 1a safety results.
Allogene says it discussed a possible registration study design with the FDA in July 2025 and believes there is alignment. It continues to explore strategic opportunities including partnerships. The next meaningful commercial facts would be a confirmed study launch or a signed collaboration with an identified financing and development plan. FDA interaction and partner strategy.
07 Diagnostic access, licenses and distribution
The selection test is part of the economic proposition for cema-cel. Foresight Diagnostics developed the investigational test used to identify residual disease in the trial. Natera acquired Foresight in December 2025, and Allogene says it continues to operate as a standalone subsidiary. Allogene expects a companion diagnostic would be needed for the population in ALPHA3. The company has discussed eligibility for selected patients in partial remission and the potential use of additional tests with the FDA. Clinical criteria and laboratory access will help determine whether the intended population can be reached in practice. Assay arrangements and regulator discussions.
The amended collaboration with Natera covers work intended to support the trial in Canada and Australia and possible development in the European Union and United Kingdom. Additional work supports trial readiness in South Korea. Those agreements help extend the infrastructure for screening and development. The operational question remains whether results can be obtained within the treatment decision window, including in community practices with different experience and resources. The September report separates development costs and clinical milestones from prospective commercial readiness. Note 6, diagnostic collaboration · Market access planning.
The intellectual-property chain for the lead program includes a sublicense through Servier from Cellectis. The 2024 Servier amendment expanded territory to the European Union and United Kingdom. Conditional options for China and Japan depend on demonstrating adequate development resources, which could be supported by a partner. Allogene owes Servier tiered royalties ranging from the low double digits to the mid-teens on annual U.S. net sales of licensed CD19-directed products it commercializes. The royalty is 10 percent on annual net sales outside the United States. Geography matters to cash flows because commercial rights and royalties vary by country. Note 6, Servier territories and royalties.
Cellectis announced in September that it was refocusing its internal portfolio on in vivo medicines and seeking partners for its own ex vivo programs. Allogene reported that Cellectis said the change leaves their existing collaboration in place. Allogene expects its existing candidates and rights to continue without a material impact based on the discussions described in the September filing. It is evaluating alternate supply for materials it sources with or from Cellectis, which is a separate operational question. Cellectis’s November 12 report continued to list cema-cel as a partner program and reiterated Allogene’s development timetable. Allogene, partner and supply disclosures · Cellectis November update.
08 September financial results and what they say about development spending
Allogene booked no collaboration revenue in either September quarter. Its net loss grew in the 2026 quarter as development spending increased. The company reports the numbers under U.S. generally accepted accounting principles. Shares outstanding rose materially after the April equity offering. The weighted-average share denominator helps explain why the per-share quarterly loss fell even as the dollar loss rose. Income statement and reporting notes.
| U.S. dollars in thousands, except per share | Q3 2026 | Q3 2025 | 9M 2026 | 9M 2025 |
|---|---|---|---|---|
| Collaboration revenue from related party | — | — | 4,640 | — |
| Research and development | 41,934 | 31,164 | 104,658 | 121,520 |
| General and administrative | 12,859 | 13,737 | 47,787 | 43,009 |
| Impairment of long-lived assets | — | — | — | 2,382 |
| Total operating expenses | 54,793 | 44,901 | 152,445 | 166,911 |
| Operating loss | (54,793) | (44,901) | (147,805) | (166,911) |
| Interest and other income, net | 4,879 | 3,926 | 13,099 | 15,629 |
| Interest expense | (379) | (344) | (1,022) | (762) |
| Other income or expense, net | (76) | (81) | 75 | (32) |
| Total other income, net | 4,424 | 3,501 | 12,152 | 14,835 |
| Net loss | (50,369) | (41,400) | (135,653) | (152,076) |
| Basic and diluted loss per share | (0.15) | (0.19) | (0.44) | (0.70) |
The quarterly increase in research and development includes $7.874 million of additional development costs and $2.511 million of additional personnel expense compared with the September 2025 quarter. Facilities and depreciation moved in the opposite direction by $0.555 million. Other research costs rose from $1.382 million to $2.322 million. The nine-month comparison shows lower research spending in part because the earlier year included higher personnel costs. The latest quarter and the nine-month period therefore describe different points in the spending cycle. Management discussion and research expense tables.
The nine-month revenue of $4.640 million reflects the accounting for termination of an Overland Therapeutics license in May. Two remaining performance obligations ended and previously deferred, nonrefundable consideration was recognized. The company surrendered 40,353,951 Overland shares for no consideration and retained approximately three percent on an as-converted, fully diluted basis after the agreement. The parties exchanged releases and made no termination payments. The cash flow statement classifies the recognized revenue as noncash. The accounting event therefore has a different impact from a customer paying for a commercial treatment. Note 6, license termination, and cash flows.
The November 5 outlook gives about $225 million of 2026 operating expenses under generally accepted accounting principles, including estimated noncash stock compensation of about $35 million. The same release gives a separate operating expense guidance of about $165 million and does not define that measure. Both estimates exclude potential business development activities. Merlintrader calculation: the $225 million accounting outlook less the $152.445 million recorded in the nine months leaves roughly $72.6 million implied for the December quarter, using the rounded annual figure. November 5 guidance · Nine-month expense statement.
09 Cash usage, escrow and runway
The September balance sheet shows $29.270 million of cash and equivalents, $263.688 million of short-term investments and $95.915 million of long-term investments. Merlintrader calculation from the reported components: $388.873 million, corresponding to the $388.9 million in the quarterly release. Restricted cash of $10.292 million is separate. The distribution between cash and securities matters because short-term investment activity can change cash on the balance sheet without changing the combined balance by the same amount. Balance sheet and restricted cash · September liquidity measure.
Reported operating cash use was $81.027 million for the nine months ended September 30, 2026, versus $121.647 million in the prior-year period. A reduction in the escrow deposit contributed $23.479 million to the operating cash flow reconciliation this year. Allogene separately reported $23.7 million of net cash proceeds from the February return of the €20 million escrow balance. The cash flow adjustment and the proceeds reported in the license note describe the same release from different accounting perspectives. A recurring burn estimate should account for the timing of that release and any deterioration in later spending. Cash flow statement and escrow release.
Merlintrader calculation: subtracting $44.909 million of first-half operating cash use from $81.027 million of nine-month use leaves $36.118 million of third-quarter use. The corresponding 2025 calculation is $121.647 million less $91.959 million, or $29.688 million. The September quarter used more cash year over year, despite the smaller first-nine-month cumulative outflow. Investing cash use of $151.031 million in the nine months mainly reflects purchases of investments net of maturities. The company spent $0.184 million on property and equipment and received net financing cash of $209.640 million. These distinctions help reconcile the capital raised to the quarter-end liquidity position. September cash flow statement · First-half cumulative cash flows.
Management expects funding into the first quarter of 2029 under its current plan. The financial statements separately state that the available resources are expected to be sufficient for at least twelve months from filing. A planning assumption into 2029 covers a longer horizon than the minimum liquidity statement. The projected primary ALPHA3 analysis is in mid-2028, so deviations in trial timing or preparation costs could consume part of the apparent buffer. A new late-stage program for kidney cancer could change requirements depending on how it is financed. Capital resources, runway and trial timetable · Annual outlook.
10 Obligations include leases and a research award
The September balance sheet presents no separate borrowings line. It shows $68.039 million of noncurrent lease liabilities and the note reports $76.936 million in total lease liabilities. Gross future lease payments are $96.102 million before the present-value adjustment. The undiscounted schedule shows $3.308 million for the rest of 2026, $13.574 million in 2027 and $79.220 million from 2028 onward (Merlintrader calculation from the lease table). A lease liability is different from a term loan and is a contractual claim on future cash. Facilities, lease commitments and outside manufacturing arrangements can affect the capacity needed to carry several programs. Balance sheet and Note 7 lease table.
California Institute for Regenerative Medicine (CIRM) funding for the kidney cancer program has performance, co-funding and potential repayment terms. Allogene received $9.2 million through September 30 after the award was amended to that maximum. It had accrued $2.3 million of interest and accounted for the proceeds as a liability in other long-term liabilities. The agreement requires up to approximately $15.7 million of Allogene co-funding. The filing identifies the award as the source of the interest expense in the income statement. This financial structure explains why interest expense appears despite the absence of a separately identified bank facility. Note 5, award terms and interest.
The award terms include a low-single-digit net-sales royalty for a funded product, with a maximum royalty equal to nine times the amount awarded and paid. After the funded project and award period end, Allogene can elect conversion to a loan through the award’s tenth anniversary. The terms could require repayment of 80 to 100 percent of the award depending on the development stage, with interest at 10 percent per year plus the Secured Overnight Financing Rate. A product that advances could therefore bring obligations under both the award and other development agreements. Evaluating possible terms for a future partner requires distinguishing these existing commitments from any new financing. CIRM terms and remaining obligations.
Allogene also has research commitments to The University of Texas MD Anderson Cancer Center. The company reports up to $15 million in total funding under the amended research collaboration, with $6 million remaining, contingent on mutually agreed study orders. The possibility of deferring certain payments depends on adequate funding for the agreed projects. This is an example of a development commitment that can follow a different schedule from facility leases or previously received grant proceeds. Contractual obligations and commitments.
11 Share issuance and compensation instruments
The November 3 outstanding share count was 346,467,307. The September 30 balance sheet reported 346,279,825 outstanding, and the December 31, 2025 balance was 229,413,523. Authorized common shares increased from 400 million at year-end to 800 million at September 30. Authorization sets a legal ceiling. Actual issued shares depend on transactions such as offerings, option exercises and the settlement of stock awards. The distinction is particularly important after a major raise has already changed the common share base. Share counts and balance sheet.
The April public offering issued 100.2 million shares at a contractual offering price of $2.00 per share, including 12.7 million under the underwriters’ partial option exercise. Gross proceeds were $200.4 million. The cash flow statement reports $187.872 million of net proceeds from that public offering. The at-the-market program was a separate issuance channel. First-quarter sales accounted for the 12,476,533 shares and $20.668 million in net proceeds reported for the first nine months. Allogene had sold no shares under the June 22 prospectus supplement at September 30, leaving its full $135 million capacity available subject to market conditions and the terms of the program. The August shelf registration creates capacity for future financing, subject to applicable offerings and prospectuses. Public offerings, changes in equity and cash flows · August shelf registration.
The filing lists 37,872,299 options, 16,707,459 outstanding restricted stock units and an estimated 1,460,674 shares under the employee stock purchase plan as excluded from diluted loss per share. The total was 56,040,432 potentially dilutive shares. It separately identified 477,000 vested and unreleased units that the per-share note says are included in weighted-average shares. The reported loss per share uses rules for an accounting period. For a capital-structure analysis, settlement, exercise, vesting and newly issued financing shares represent separate sources of change. Notes 8 and 12, equity awards and loss per share.
The filing discusses warrants acquired by Allogene for shares of Antion as part of a separate investment arrangement. Those instruments concern Antion’s preferred stock. Allogene’s own latest loss-per-share table lists the option, unit and employee purchase plan categories above. That distinction keeps the invested company’s contractual securities separate from the securities that could change the number of Allogene shares. Note 6, Antion investment, and Note 12.
12 Ownership changes and market liquidity
The November 16 joint Schedule 13G reports 24,680,425 shares of aggregate beneficial ownership, or 7.1 percent, for Kenneth C. Griffin at September 30. The filing shows 16,352,007 shares (4.7 percent) in the Citadel Securities reporting chain and 8,328,418 shares (2.4 percent) in the Citadel Advisors reporting chain. Those positions are included in the reported aggregate. The filing calculates percentages using 345,490,881 common shares outstanding at August 10, as disclosed in the June report. The share count in the later September Form 10-Q has a different measurement date. November 16 joint Schedule 13G · June filing cover.
State Street Corporation’s November 10 Schedule 13G reports 16,326,197 shares (4.7 percent) at September 30 and marks its exit from the over-five-percent category. Its August 7 filing reported 19,025,826 shares, or 5.5 percent, as of June 30. BlackRock, Inc.’s October 27 amendment reported 23,211,736 shares (6.7 percent) at September 30 for its reporting units. Frazier Life Sciences Public Fund, L.P. reported in an August 14 Schedule 13G/A that it directly held 19,445,046 shares (5.6 percent) at June 30. Arie Belldegrun’s August 7 Schedule 13G reported 13,610,578 shares, including options exercisable within 60 days, or 3.9 percent at June 30, which is below five percent and follows a May 13 report of 5.4 percent. TPG’s September 30 amendment reports a sale of 18,716,306 shares on September 28 and that the reporting persons no longer beneficially owned any Allogene common shares. The holders made the sale under Rule 144. The offering and issuance amounts in Allogene’s financial statements concern different transactions. State Street November disclosure · State Street prior filing · BlackRock amendment · Frazier amendment · Belldegrun Schedule 13G · TPG exit amendment.
Geoffrey Parker’s October 23 Form 4 records a sale of 36,342 shares on October 21 with transaction code S. The filing describes a required sale to cover taxes on vested restricted stock units and reports 1,045,877 shares following the transaction. The board appointed Annie Yoshiyama interim principal financial officer on November 3, effective with Parker’s retirement on November 6. The company had begun an external search. Zachary Roberts became president and chief executive on July 1, 2026. David Chang stepped down on June 30 and continued on the board as a non-employee director. Parker Form 4 · Leadership transitions · Roberts employment agreement.
Nasdaq’s October 30 short-interest settlement shows 51,285,271 shares short and average daily volume of 8,270,990 shares, corresponding to 6.20 days to cover. October 15 figures were 53,405,256 short and a comparison volume of 5,775,784, corresponding to 9.25 days. The decline in the ratio reflects both fewer reported short positions and more volume. Reported short positions show positioning at the settlement date. The Financial Industry Regulatory Authority (FINRA) lists November 24 as the publication date for the November 13 settlement. Nasdaq data report · Nasdaq reporting definitions · Publication calendar.
13 What can change the value of the pipeline
Licensing disputes can influence the timetable even when the medical evidence is unchanged. In December 2025 Cellectis reported that an arbitral tribunal partially terminated the Cellectis–Servier agreement with respect to the predecessor ALLO-501 and affirmed continuing rights for cema-cel. As a result, Allogene’s Servier license for ALLO-501 ended, as disclosed in the September filing. In April 2026, Life Technologies Corporation asserted that it had terminated certain license agreements with Cellectis and disputed rights that Cellectis had made available to Allogene. Cellectis disputes the termination and the claims. Allogene says it is outside that arbitration and continues to assess the effect on its rights. Note 6, two separate licensing disputes.
A separate patent infringement action in the U.S. District Court for the District of Delaware, Civil Action No. 25-1197, involves Factor Bioscience, Cellectis and AstraZeneca Ireland Limited. The September risk factors describe potential effects on Allogene through its use of licensed intellectual property and state that Allogene is not a party. On May 5, 2026, the Patent Trial and Appeal Board declared an interference (No. 106,318) over the patents asserted in the case. A June 29 court order stayed the case at least through the Board’s motions phase in that interference. If Factor Bioscience does not prevail on its motions there, the stay continues until the interference is finally resolved. The order addresses timing and leaves the merits unresolved. Patent risk disclosure · June 29 court order.
The dependency on Foresight has previously been tested in litigation. The September filing says Foresight announced a limited license with the Roche parties in August 2025 and the claims were dismissed with prejudice. The dispute illustrates a practical risk because a need to replace a selection assay could change the trial timetable and the regulatory work. The selection test and the underlying treatment licenses therefore remain separate inputs to the valuation. Risk factors on the diagnostic and licensing.
In the coming year the strongest operating developments would be progress in screening and recruitment, consistent completion of treatment across sites, and plans to carry the next stages with resources on hand or committed partners. The pivotal value question will become clearer when Allogene reports the clinical outcome comparison for ALPHA3. A favorable result would bring further questions about patient selection, treatment-site economics and licensing. A delay or a weaker result would place more of the financing burden on an early autoimmune program and a kidney cancer program still seeking a path forward. Clinical, financing and licensing outlook.
Merlintrader Health Score · $ALLO
2.65out of 5
Assessed November 20, 2026. Merlintrader calculation: 3.5 × 30% + 2.5 × 30% + 1.5 × 20% + 3.0 × 10% + 2.5 × 10% = 2.65 out of 5.
ALLO red flags
- Pivotal clinical outcome pending. The April ALPHA3 analysis measured residual disease, while the primary clinical endpoint remained blinded. April assessment.
- Prior serious safety event in ALPHA3. A fatal event led Allogene to discontinue the earlier ALLO-647 arm in July 2025. The ongoing trial uses a different lymphodepletion regimen. ALPHA3 safety history.
- Small early autoimmune sample. Skin-score observations came from a subset, and treatment-emergent serious events were reported in the larger safety cohort. Safety and efficacy tables.
- Diagnostic and license dependencies. The investigational selection test and rights through partners are both important to the intended lymphoma strategy. Risk disclosures.
- Financing across long timelines. Operating cash use and existing commitments continue ahead of the primary ALPHA3 window. Cash flows and program schedule.
ALLO Stock FAQ: Allogene Therapeutics, Inc. Questions Answered
What is the next scheduled catalyst for Allogene?
December 2, 2026 is Allogene’s next scheduled investor conference. Allogene expects its next ALPHA3 clinical update in mid-2027, with timing and scope subject to the available trial data and oversight. Conference listing · Trial timetable.
What is the FDA status of Allogene’s cema-cel?
In July 2026, the FDA granted Fast Track and Regenerative Medicine Advanced Therapy designations for the first-line consolidation program. Cema-cel remains investigational in the pivotal Phase 2 ALPHA3 trial. Designations and trial status.
How much does ALLO have in cash and investments?
Allogene reported $388.9 million in cash, equivalents and investments at September 30, 2026. Management expects the funding to last into the first quarter of 2029 under its current operating plan. Liquidity outlook · September results.
What could dilute ALLO stockholders?
On November 3, 2026, Allogene had 346,467,307 common shares outstanding. Additional market offerings can increase that number, as can option exercises and the settlement of equity awards. Share count and financing options.
When did Allogene last report results?
Allogene announced September-quarter results on November 5, 2026. The reported net loss was $50.369 million, with no collaboration revenue in the quarter. The Form 10-Q has a November 6 filing date. Results release · Form 10-Q statements.
What does Allogene Therapeutics develop?
The November 5, 2026, update describes donor-derived CAR T-cell candidates for oncology and autoimmune disease. The core programs are cema-cel in lymphoma, ALLO-329 in autoimmune disease and ALLO-316 in advanced kidney cancer. November update · Business overview.
What did Allogene report for the ALLO-329 trial?
On November 9, 2026, Allogene reported early safety findings in 18 people and skin-score results in a subset of ten. Eight in that subset had a sustained five-point or greater improvement in the modified Rodnan skin score. The data come from an early open-label study. RESOLUTION disclosure.
Sources
- September Form 10-Q · June Form 10-Q · 2025 Form 10-K · November 5 results exhibit · Press release archive
- April interim ALPHA3 announcement · ALPHA3 study record · November 9 findings · RESOLUTION poster · RESOLUTION study record · TRAVERSE registry
- ALPHA2/ALPHA, Journal of Clinical Oncology, 2025 · HOVON-902, Journal of Clinical Oncology, 2026 · ZUMA-7, NEJM, 2022 · TRAVERSE, Journal of Clinical Oncology, 2026
- Immunotherapy meeting program · Piper Sandler date · Hematology annual meeting · November 20 Allogene ASH announcement · Cellectis November update · Patent litigation stay order
- November Citadel Schedule 13G · November State Street Schedule 13G · October BlackRock amendment · September TPG exit · August Frazier Schedule 13G/A · August Belldegrun Schedule 13G · October Form 4 · Nasdaq short interest
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $ALLO or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, court records and market-data providers, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.
Biotechnology and pharmaceutical companies carry clinical, regulatory, commercial and financing risk, including dilution, and readers can lose capital. Readers are responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



